Your Cart

Cleansing Notice – Entitlement Offer Shares

Cleansing Notice – Entitlement Offer Shares

This notice is given by Imagion Biosystems Limited (the ‘Company’ or ‘IBX’) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (‘Corporations Act’) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84 and ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73.

On 7 March 2023 the Company announced that it will undertake a non-underwritten pro rata nonrenounceable entitlement offer of one (1) fully paid ordinary share in IBX (‘New Share’) for every eight (8) existing ordinary shares held in IBX as at 7.00pm (AEDT) on 10 March 2022. The offer will be made to existing shareholders with a registered address in Australia, New Zealand and certain other jurisdictions in which IBX decides to extend the offer to raise up to approximately $2.4 million (‘Entitlement Offer’).

Further details of the Entitlement Offer are contained in the announcement made by the Company and an information booklet lodged with the ASX on 7 March 2023.

The Company gives notice that:

a. the Company will be offering the shares for issue without disclosure to investors under Part 6D.2 of the Corporations Act;

b. this notice is being given under section 708AA(2)(f) of the Corporations Act;

c. as at the date of this notice the Company has complied with:

i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

ii. sections 674 and 674A of the Corporations Act;

d. as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act that is required to be set out in this notice under section 708AA(7) of the Corporations Act; and

e. the potential effect that the Entitlement Offer will have on the control of IBX and the consequences of that effect will depend on various factors, including investor demand and existing shareholders. However, given:

i. the size and pricing of the Entitlement Offer;

ii. the structure of the Entitlement Offer as a pro rata non-renounceable issue; and

iii. the current level of substantial holdings (based on substantial holding notices that have been given to IBX and lodged with ASX on or prior to the date of this notice);

the issue of new shares under the Entitlement Offer is not expected to have any material effect or consequence on the control of the Company.


About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

Authorisation & Additional information
This announcement was authorised by the Board of Directors of Imagion Biosystems Limited

Additional PDFs regarding the announcement: 

Questions about this announcement or other investor-related inquiries? Please email our investor relations department at:

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.